Q4
1.6.2022 15:02:07 CEST | Business Wire | Press release
Q4 Inc. (TSX: QFOR) (“Q4”), a leading capital markets communications platform provider, is excited to announce the launch of Q4 Capital Connect ™, a revolutionary, scalable platform built to streamline workflows and provide data-driven strategic insights across the capital markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005573/en/
Q4 Capital Connect™ enables public companies across all industries and market caps to seamlessly launch and measure the impact of a complete investor relations strategy. With one place to launch how they communicate their value to the markets, analyze the impact of every outreach, target and engage with the right investors, IR teams can build a repeatable, proactive strategy to connect with the capital markets. The platform approach allows all data generated by investors across an IR program to be aggregated alongside shareholder analytics for insights to shape a communication strategy that investors value while identifying and prioritizing the shareholders that matter.
The Q4 Capital Connect platform will house a portfolio of future applications, purpose-built to empower capital markets professionals. The first of these applications include Q4 Engagement Analytics and Q4 Web Management .
The Engagement Analytics application on Q4 Capital Connect™ aggregates the actions of investors and shareholders visiting an investor relations website and IR-related events, turning behavioral data into powerful leading indicators of stock movement, ownership data and surveillance to drive a new and proactive approach to investor targeting. Through these analytics, IROs can identify which new, existing or targeted institutions are assessing content, analyze interactions at the early stages of an investor’s research, prioritize their management team’s time to proactively engage with the right investor, and accelerate management’s awareness of activist interest in the company.
Engagement Analytics is the first product in the market that uniquely combines investor behavior with the buying and selling of publicly traded securities. This provides the ability to understand investors’ actions and intent on a daily basis and takes proactive targeting to a new level.
The fully integrated Web Management application on Q4 Capital Connect™ provides a frictionless and simplified approach to managing an IR website, offering one destination to request, track and approve critical updates to the market. Q4’s secure platform connects users with the Q4 Content Services team to easily request, preview, and publish changes to their website, while tracking change history in the same place. To date there are over 1,300 Q4 clients already using the web management application, who have experienced up to a 57% reduction in interactions when requesting content updates, a 35% improvement in turnaround times, and a vastly improved overall user experience.
“The launch of Q4 Capital Connect™ is just the beginning of a transformational approach to drive strategic, efficient and more effective interactions across the capital markets,” said Darrell Heaps, Q4’s CEO. “Built on proprietary data and analytics, along with an ever increasing portfolio of digital communication solutions, Q4 Capital Connect is a scalable platform that will continue to expand to an increasing number of applications for investor relations, as well as key workflows for investment banks and investors. We are very excited to introduce Q4 Capital Connect™ and demonstrate the strategic value and efficiencies we can provide to all capital markets participants when they come onto the Q4 platform.”
To learn more about Q4 Capital Connect™ please click here .
About Q4 Inc.
Q4 Inc. (TSX: QFOR) is a leading capital markets communications platform that is transforming the way publicly traded companies, investors and investment banks make decisions to efficiently discover, communicate and engage with each other. The Q4 end-to-end technology platform facilitates interactions across the capital markets through its IR website products, virtual events solutions, capital markets CRM, shareholder and market analytics tools. The firm is a trusted partner to more than 2,700 public companies globally including many of the most respected brands in the world. Q4 is based in Toronto, with offices in New York and London. Learn more at q4inc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005573/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Technology Innovation Institute Completes Asteroid-Landing Probe for Landmark Emirates Mission to the Asteroid Belt5.10.2026 09:42:00 CEST | Press release
In a first-of-its-kind mission, TII’s probe aboard the MBR Explorer will journey past six asteroids in the main belt before landing on 269 Justitia, making it only the seventh asteroid in history to be reached on its surface by a probeDesigned, built and tested in Abu Dhabi, TII’s probe is the mission’s only deployable payload, operating fully autonomously around and on JustitiaThought to have formed in the distant Kuiper Belt in the outer Solar System, 269 Justitia may preserve clues to how water and organic material were distributed during the formation of the planetsWatch the EMA hero film here The Technology Innovation Institute (TII) has revealed the UAE-built probe it has developed for the Emirates Mission to the Asteroid Belt (EMA). The probe will soon travel to Colorado, USA, for final integration with the MBR Explorer spacecraft ahead of its planned 2028 launch. In a historic first, TII’s probe will image two planets and seven asteroids — flying past six asteroids in the main
JEOL: Sales launch of HAXIS: The New Low-angle Ion Milling Scanning Electron Microscope5.10.2026 09:30:00 CEST | Press release
JEOL Ltd. (President & CEO Izumi Oi) announces the development of its new low‑angle ion‑milling scanning electron microscope, HAXIS, and will commence sales on October 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928207899/en/ HAXIS Low-angle Ion Milling Scanning Electron Microscope HAXIS Low-angle Ion Milling Scanning Electron Microscope Background of development As advanced semiconductor device structures continue to shrink and grow more complex, it has become difficult to contact and measure microscale circuits using nano-manipulators. In addition, contact caused by probing may affect the analysis target, necessitating new failure analysis methods. JEOL has conducted long-term research on the passive voltage contrast (PVC) detection technology and established a method for stable, highly reproducible PVC observation technology through the advancement of detectors and sample preparation techniques. HAXIS is JE
Slate Asset Management and OneIM Agree to Acquire Portfolio of Grocery-Anchored Essential Real Estate in the Greater Oslo Region Valued at Approximately €250 Million5.10.2026 08:30:00 CEST | Press release
Slate Asset Management ("Slate"), a global investor and manager focused on essential real estate and infrastructure assets, and One Investment Management (“OneIM”), a global alternative investment manager, today announced they have agreed to acquire a portfolio of eight grocery-anchored retail parks in Norway from Tellus Eiendom AS. The portfolio is located in the Greater Oslo region and is anchored by Norway's leading grocery operators and discount retailers. “We are pleased to be expanding our European Essential real estate platform with this significant acquisition,” said Brady Welch, Co-Founding Partner of Slate Asset Management. “These eight retail parks sit in dominant locations along major transport corridors around Oslo. The portfolio is anchored by Norway's strongest grocery operators and benefits from CPI-linked lease structures, designed to provide durable, inflation-protected cash flows. We look forward to applying our active management to unlock the portfolio’s full potent
Bial Showcases Parkinson’s Research at MDS 20265.10.2026 08:00:00 CEST | Press release
New data provide insights into the experiences and perceptions of people living with Parkinson’s and treatment outcomes Three posters and one oral presentation focus on the discontinued investigational compound BIA 28-6156 [INTENDED FOR MEDICAL AND TRADE MEDIA ONLY] Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, is presenting 16 scientific posters at the International Congress of Parkinson’s Disease and Movement Disorders (MDS 2026), taking place in Seoul, Korea, from 4 to 8 October. Reflecting Bial’s commitment to listening to and learning directly from people living with Parkinson’s, two presentations cover research initiatives focused on understanding their experiences, perspectives, and priorities. The first is the Patient Endpoint Preference Project (PEPP), an ongoing multinational observational study that seeks to identify and prioritise the symptoms and outcomes that matter most to people living with Parkinson’s. The second is th
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press release
Survival estimate remained at 48% between years two and three, extending evidence of durable benefitResults observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of therapy; nearly three-quarters of patients had platinum-resistant or refractory cancer Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom